IRIS
VERGARO, Giuseppe
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 18.803
EU - Europa 9.261
AS - Asia 8.729
SA - Sud America 2.772
AF - Africa 219
Continente sconosciuto - Info sul continente non disponibili 25
OC - Oceania 19
Totale 39.828
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 18.028
SG - Singapore 3.638
RU - Federazione Russa 3.172
BR - Brasile 2.272
CN - Cina 2.055
IT - Italia 2.051
VN - Vietnam 1.342
GB - Regno Unito 1.291
DE - Germania 738
CA - Canada 561
HK - Hong Kong 546
UA - Ucraina 439
IE - Irlanda 248
SE - Svezia 237
FR - Francia 219
AR - Argentina 197
IN - India 176
FI - Finlandia 173
MX - Messico 160
PL - Polonia 153
BD - Bangladesh 136
ID - Indonesia 136
TR - Turchia 132
DK - Danimarca 122
IL - Israele 114
NL - Olanda 108
ZA - Sudafrica 103
EC - Ecuador 93
ES - Italia 93
JP - Giappone 89
IQ - Iraq 79
AT - Austria 71
PK - Pakistan 64
CO - Colombia 57
AE - Emirati Arabi Uniti 42
PY - Paraguay 40
LT - Lituania 39
UZ - Uzbekistan 39
MA - Marocco 36
PE - Perù 27
CL - Cile 26
VE - Venezuela 26
EU - Europa 21
UY - Uruguay 20
KE - Kenya 18
TN - Tunisia 15
AZ - Azerbaigian 14
BE - Belgio 14
SA - Arabia Saudita 14
EG - Egitto 13
JO - Giordania 12
RO - Romania 12
BO - Bolivia 11
CH - Svizzera 11
DZ - Algeria 10
IR - Iran 10
KZ - Kazakistan 10
DO - Repubblica Dominicana 9
PH - Filippine 9
AU - Australia 8
HN - Honduras 8
MC - Monaco 8
NZ - Nuova Zelanda 8
AM - Armenia 7
CR - Costa Rica 7
CZ - Repubblica Ceca 7
AL - Albania 6
BY - Bielorussia 6
JM - Giamaica 6
LB - Libano 6
NI - Nicaragua 6
OM - Oman 6
TH - Thailandia 6
KW - Kuwait 5
NP - Nepal 5
PA - Panama 5
TW - Taiwan 5
BB - Barbados 4
BG - Bulgaria 4
BH - Bahrain 4
CI - Costa d'Avorio 4
GE - Georgia 4
HU - Ungheria 4
KR - Corea 4
NG - Nigeria 4
SK - Slovacchia (Repubblica Slovacca) 4
TT - Trinidad e Tobago 4
AO - Angola 3
GR - Grecia 3
GT - Guatemala 3
GY - Guiana 3
IS - Islanda 3
LU - Lussemburgo 3
MD - Moldavia 3
MK - Macedonia 3
MY - Malesia 3
PS - Palestinian Territory 3
RS - Serbia 3
SM - San Marino 3
BA - Bosnia-Erzegovina 2
Totale 39.784
Salva come PNG Salva come JPEG
Città #
Dallas 4.487
Singapore 1.958
Chicago 1.210
Ashburn 1.052
Beijing 1.001
Los Angeles 917
Moscow 584
Southend 540
Salt Lake City 526
Hong Kong 504
Chandler 443
Ho Chi Minh City 436
Fairfield 411
Buffalo 364
Woodbridge 330
San Mateo 329
Houston 327
Tampa 298
New York 280
Wilmington 278
Seattle 268
Ann Arbor 243
Dublin 240
Cambridge 236
São Paulo 233
Falls Church 232
Hanoi 232
Elk Grove Village 230
The Dalles 229
Hefei 218
Boardman 204
Jacksonville 183
Ottawa 182
Milan 181
Dearborn 162
Beauharnois 155
Portsmouth 153
Munich 145
Pisa 144
Stevenage 141
Santa Clara 135
Warsaw 133
Rome 128
Sterling 117
Dong Ket 115
Lawrence 106
Brooklyn 105
Lancaster 105
Tel Aviv 103
Montreal 99
London 95
Florence 88
Poplar 88
Rio de Janeiro 79
Tokyo 79
Miami 77
Denver 75
Frankfurt am Main 75
Phoenix 75
Istanbul 72
Johannesburg 72
Stockholm 72
Atlanta 66
Dulles 65
Mexico City 64
Orem 63
Chennai 62
Nuremberg 62
Belo Horizonte 53
Turku 51
Helsinki 50
San Diego 47
Lappeenranta 46
Detroit 45
Kansas City 45
Toronto 45
Manchester 43
Amsterdam 42
Boston 42
Brasília 41
Querétaro 41
Da Nang 39
Fremont 39
Haiphong 39
Washington 39
Porto Alegre 38
Curitiba 37
Redwood City 36
San Francisco 36
Tashkent 36
Council Bluffs 35
Biên Hòa 34
Bologna 34
Pittsburgh 34
Guangzhou 33
Ankara 32
Quito 32
Guayaquil 31
Lucca 31
Genoa 30
Totale 24.017
Salva come PNG Salva come JPEG
Nome #
Prognostic value of soluble ST2 in AL and TTR cardiac amyloidosis: a multicenter study 1.794
N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin T hold diagnostic value in cardiac amyloidosis 1.600
Cardiac remodelling - Part 2: Clinical, imaging and laboratory findings. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology 1.511
High prevalence of wild-type transthyretin cardiac amyloidosis in older adults with carpal tunnel syndrome, heart failure or increased left ventricular mass: The CAPTURE study 662
Valutazione delle caratteristiche analitiche e dei risultati clinici di un metodo in chemiluminescenza a cattura di microparticelle (CMIA) per il dosaggio della Galectina-3 sulla piattaforma ARCHITECT 658
Patient-reported outcome measures for transthyretin cardiac amyloidosis: the ITALY study 551
[18F]-Florbetaben PET/CT for Differential Diagnosis Among Cardiac Immunoglobulin Light Chain, Transthyretin Amyloidosis, and Mimicking Conditions 332
Trastuzumab cardiotoxicity and drug cardioprotection in healthy and cardiac dysfunction mouse models 328
A simple echocardiographic score to rule out cardiac amyloidosis 307
Measurement of myocardial amyloid deposition in systemic amyloidosis: insights from cardiovascular magnetic resonance imaging 298
Value of the HFA-PEFF and H2FPEF scores in patients with heart failure and preserved ejection fraction caused by cardiac amyloidosis 296
Markers of fibrosis, inflammation, and remodeling pathways in heart failure 281
Bidirectional Relationship Between Cancer and Heart Failure: Insights on Circulating Biomarkers 281
Adrenergic activation in heart failure: blockade or rebalance? 276
Prognostic Value of Soluble Suppression of Tumorigenicity-2 in Chronic Heart Failure: A Meta-Analysis 276
Targeting Mitochondrial Dysfunction in Chronic Heart Failure: Current Evidence and Potential Approaches 269
A simple echocardiographic score to rule out cardiac amyloidosis 258
Galectin-3 and myocardial fibrosis in nonischemic dilated cardiomyopathy 258
Prognostic Value of High-Sensitivity Troponin T in Chronic Heart Failure: An Individual Patient Data Meta-Analysis 249
Meta-Analysis of Soluble Suppression of Tumorigenicity-2 and Prognosis in Acute Heart Failure 247
CHADS2 and CHA2DS2-VASc scores to predict morbidity and mortality in heart failure patients candidates to cardiac resynchronization therapy 243
A mechanistic look at sacubitril/valsartan action. Unravelling magician's secrets 241
Admission high-sensitivity troponin T and NT-proBNP for outcome prediction in acute heart failure 239
Clinical relevance of non-cardiac determinants of natriuretic peptide levels. 237
Sex-related differences in chronic heart failure 235
Biomarkers of activation of renin-angiotensin-aldosterone system in heart failure: how useful, how feasible? 234
Cardiac light-chain deposition disease relapsing in the transplanted heart 234
How to take arms against central apneas in heart failure 234
Cheyne-Stokes respiration related oscillations in cardiopulmonary hemodynamics in patients with heart failure 232
Prognostic significance of myocardial extracellular volume fraction in nonischaemic dilated cardiomyopathy 229
Arterial thrombo-embolic events in cardiac amyloidosis: a look beyond atrial fibrillation 228
[Rationale and significance of the Italian Network for Cardiac Amyloidosis] 224
A national survey on prevalence of possible echocardiographic red flags of amyloid cardiomyopathy in consecutive patients undergoing routine echocardiography: study design and patients characterization - the first insight from the AC-TIVE Study 223
Are big data on myocardial infarction enough for small heart failure patients? Lessons from a national registry 222
Update sui biomarcatori nello scompenso cardiaco. 221
[18F]-florbetaben PET/CT is sensitive for cardiac AL amyloidosis 221
Screening the health status of people working in a university 219
Body mass index and outcomes in ischaemic versus non-ischaemic heart failure across the spectrum of ejection fraction 219
Approach to the diagnosis and management of patients with cardiac amyloidosis. A consensus document by the Tuscan section of the Italian Association of Hospital Cardiologists (ANMCO) and the Tusco-Umbrian section of the Italian Society of Cardiology (SIC) 219
Predicting readmissions after hospitalization for heart failure: Medical reasoning vs calculators 218
Breathing Not Properly in the oldest old. Is brain natriuretic peptide a poor test for the diagnosis of heart failure in the elderly? 217
Refractory hyperaldosteronism in heart failure is associated with plasma renin activity and angiotensinogen polymorphism 215
NT-proBNP prognostic value is maintained in elderly and very elderly patients with chronic systolic heart failure 215
Effect of Sex on Reverse Remodeling in Chronic Systolic Heart Failure 215
[Ten perspectives for research and innovation in cardiac amyloidosis] 212
Circulating levels and prognostic cut-offs of sST2, hs-cTnT, and NT-proBNP in women vs. men with chronic heart failure 207
In Vivo Murine Models of Cardiotoxicity Due to Anticancer Drugs: Challenges and Opportunities for Clinical Translation 207
Wild-type transthyretin cardiac amyloidosis is not rare in elderly subjects: the CATCH screening study 206
Central And Obstructive Apneas in Heart Failure With Reduced, Mid-Range And Preserved Ejection Fraction. 206
Contribution of the lung to the genesis of cheyne-stokes respiration in heart failure: Plant gain beyond chemoreflex gain and circulation time 206
Inhibition of Galectin-3 Pathway Prevents Isoproterenol-Induced Left Ventricular Dysfunction and Fibrosis in Mice 205
Atrial amyloidosis: mechanisms and clinical manifestations 204
Prognostic value of reverse remodelling criteria in heart failure with reduced or mid-range ejection fraction 204
Biomarkers for the diagnosis and management of heart failure 203
Correction of procedural arterial pseudoaneurysms: Established and novel procedures 199
Prognostic value of plasma Renin activity in heart failure. 198
Amyloid deposits and fibrosis on left ventricular endomyocardial biopsy correlate with extracellular volume in cardiac amyloidosis 195
The search for efficient diagnostic and prognostic biomarkers of heart failure 194
Biomarkers for the diagnosis and management of heart failure: New frontiers 194
Eligibility for vericiguat in a real‐world, contemporary heart failure population 191
Patients with cardiac amyloidosis have a greater neurohormonal activation than those with non-amyloidotic heart failure 189
Arrhythmic risk prediction in non-dilated left ventricular cardiomyopathy: The role of overlap with arrhythmogenic cardiomyopathy 188
Modern diagnostic and therapeutical approach to cardiac AL amyloidosis and neuroendocrine model of heart failure: lessons from a clinical case. 187
Noncardiac Versus Cardiac Mortality in Heart Failure With Preserved, Midrange, and Reduced Ejection Fraction 186
Biomarkers for the diagnosis and management of heart failure: Natriuretic peptides 185
Role of Imaging in Cardiomyopathies 181
Clinical and prognostic significance of central and obstructive apnoeas in patients with transthyretin cardiac amyloidosis 181
Sacubitril–valsartan treatment is associated with decrease in central apneas in patients with heart failure with reduced ejection fraction 180
Keys to early diagnosis of cardiac amyloidosis: red flags from clinical, laboratory and imaging findings 180
Central apnoeas and ticagrelor-related dyspnoea in patients with acute coronary syndrome 180
Beta-blocking patients with cardiac amyloidosis: Adelante cum juicio 179
Upright Cheyne-Stokes Respiration in Patients With Heart Failure 179
Echocardiographic findings in subjects with an amyloidogenic apolipoprotein A1 pathogenic variant 176
Cardiogenic shock and acute kidney injury: the rule rather than the exception 176
Renin profiling predicts neurohormonal response to sacubitril/valsartan 176
Discharge FGF23 level predicts one year outcome in patients admitted with acute heart failure 176
A prognostically meaningful definition of non-dilated left ventricular cardiomyopathy 176
Management of complications of cardiac amyloidosis: 10 questions and answers 175
Subclinical cardiac damage in cancer patients before chemotherapy 174
Abdominal Fat Biopsy for the Diagnosis of Cardiac Amyloidosis 174
Valvular heart disease in patients with cardiac amyloidosis 171
Disease features and management of cardiomyopathies in women 171
Molecular autopsy of sudden cardiac death in the genomics era 170
Cardiac amyloidosis characterization by kinetic model fitting on [18F]florbetaben PET images 169
Clinical and Prognostic Significance of sST2 in Heart Failure: JACC Review Topic of the Week 169
Multiparametric Echocardiography Scores for the Diagnosis of Cardiac Amyloidosis 168
Biomarkers in heart failure clinical trials. A review from the Biomarkers Working Group of the Heart Failure Association of the European Society of Cardiology 167
Deep-learning-based cardiac amyloidosis classification from early acquired pet images 167
Classification of patients with cardiac amyloidosis using machine learning models on Italian electronic clinical health records 167
Epidemiological and clinical boundaries of heart failure with preserved ejection fraction 166
[Diagnostic-therapeutic care pathways for patients with cardiac amyloidosis - SIC/ANMCO Consensus document. Edited by the Italian Cardiac Amyloidosis Network (RIAC)] 166
Diphosphonate single-photon emission computed tomography in cardiac transthyretin amyloidosis 166
Deep learning to diagnose cardiac amyloidosis from cardiovascular magnetic resonance 165
Heart, kidney and FGF23: Les liaisons dangereuses 164
Biopsy Evidence of Sequential Transthyretin and Immunoglobulin Light-Chain Cardiac Amyloidosis in the Same Patient 164
Early diagnosis, disease stage and prognosis in wild-type transthyretin amyloid cardiomyopathy: The DIAMOND study 163
Central Apneas Are More Detrimental in Female Than in Male Patients With Heart Failure 162
Percorsi diagnostico-terapeutici assistenziali per i pazienti con amiloidosi cardiaca – Documento di consenso SIC/ANMCO. A cura della Rete Italiana dell’Amiloidosi Cardiaca (RIAC) 161
N-terminal fraction of pro-B-type natriuretic peptide versus clinical risk scores for prognostic stratification in chronic systolic heart failure 161
RNA-targeting and gene editing therapies for transthyretin amyloidosis 160
Totale 26.312
Salva come PNG Salva come JPEG
Categoria #
all - tutte 203.615
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 203.615
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.512 0 0 0 0 0 286 198 136 187 151 243 311
2021/20221.911 161 295 80 196 74 67 201 333 141 195 36 132
2022/20231.334 109 110 62 140 164 175 36 120 251 30 82 55
2023/20241.331 76 36 239 101 73 120 102 65 51 75 55 338
2024/202513.502 112 132 487 200 420 489 1.183 2.120 812 2.024 3.134 2.389
2025/202617.282 1.474 4.063 3.958 3.848 2.785 1.154 0 0 0 0 0 0
Totale 40.103